Any cloudiness suggests protein aggregation, where degraded peptide molecules clump together
Benefit of Semaglutide in PAD seen in STRIDE is consistent regardless of PAD severity at baseline or age
GLP-1RAs have been proven to reduce the risk of major adverse cardiovascular events (MACE) occurrence, including death from cardiovascular causes, non-fatal myocardial infarction and non-fatal stroke, as well as all-cause mortality in T2DM and patients with obesity ( The glucocorticoid receptors are present in GLP-1-producing cells, and their activation diminishes the secretory responsiveness of these cells ( 4.1 Efficacy of GLP-1 receptor agonist therapy in SID Considering their beneficial effects on body weight, effective glycemic control, and low risk of hypoglycaemia, GLP-1 RAs may be suitable therapeutic options for SID and SIH, either as adjunctive therapy or as primary treatment
You have tried a non-GLP-1 medication for diabetes, such as metformin
Martinez, D
Longo C, Rito C, Beretti F, et al